|
| News |
| NEWS ARCHIVE | Relypsa appoints Ronald A. Krasnow Senior Vice President, Intellectual Property and Chief Patent Counsel |
|
|
Santa Clara, CA, January 9, 2008 — Relypsa, Inc., a privately-held biopharmaceutical company discovering and developing novel polymeric drugs, today announced the appointment of Ronald Krasnow as Senior Vice President, Intellectual Property & Chief Patent Counsel. In this newly-created position, he will be responsible for overseeing all activities related to ensuring solid intellectual property (IP) protection for Relypsa’s technology and product portfolios. Mr. Krasnow will also oversee corporate and transactional legal activities on behalf of the company. He will report to Jay Shepard, President and Chief Executive Officer of Relypsa. Mr. Krasnow joins Relypsa with more than twenty years of experience focused on worldwide intellectual property development and management in the biotechnology, pharmaceutical and chemical industries. Notably, he held senior-level responsibility at Symyx Technologies, Inc., where he filed applications leading to more than 350 issued patents worldwide, many in the field of polymeric products. In addition, Mr. Krasnow gained firsthand experience in patent examination while working at the United States Patent and Trademark Office. “Ron’s extensive experience in patent portfolio management, and specifically, his expertise in intellectual property rights around polymeric structures will make him an invaluable asset,” said Jay Shepard. “The addition of Ron to our management team underscores our premier expertise in polymeric drug discovery and development and our commitment to building Relypsa’s patent portfolio.” "I am delighted to be joining Relypsa’s management team at this exciting stage,” said Mr. Krasnow. “As a young company with such a strong product portfolio, innovative discovery platform, committed investors and accomplished leadership, I believe Relypsa is poised for success. I am pleased to be able to oversee all legal activities for Relypsa, enabling our scientists to discover and develop new polymeric drugs that will address significant medical needs.” Mr. Krasnow most recently served at Symyx Technologies, Inc. as Senior Vice President, Intellectual Property, responsible for Symyx’s intellectual property rights in the fields of high throughput methods, equipment, software and materials. As the first in-house attorney at Symyx in 1997, Mr. Krasnow created, managed and licensed the company’s IP portfolio including worldwide patent development. Previously, Mr. Krasnow was an attorney at Fish & Neave in New York representing clients in complex patent litigation and interferences. He has also served as a Patent Examiner at the United States Patent and Trademark Office. Mr. Krasnow received his Juris Doctor from The George Washington University, National Law Center and his Bachelor of Science degree in Materials and Metallurgical Engineering from The University of Michigan. About Relypsa, Inc. Relypsa, Inc. is a biopharmaceutical company leading the discovery and development of new non-absorbed polymeric drugs for important applications in renal and cardiovascular disease. The company’s most advanced therapeutic programs include a novel potassium binder for treatment of hyperkalemia, known as RLY-105. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform. Privately-held, the company’s investors include 5AM Ventures, New Leaf Venture Partners, The Sprout Group, Delphi Ventures, CMEA Ventures and Mediphase Venture Partners. For further information about the company, please see www.relypsa.com. CONTACT: Reypsa, Inc. |
|
© 2009 Relypsa, Inc |